Sep 2026· International Immunopharmacology· pp.
117442
· 0 citations· 53 references
Medicine
TL;DR
It is demonstrated for the first time that Farrerol alleviates HIRI by downregulating macrophage CD14 expression, thereby inhibiting the downstream MyD88/NF-κB pathway and its associated inflammatory cascade, positioning FA as a promising therapeutic candidate and highlighting CD14 as a viable target for HIRI intervention.
Abstract
Hepatic ischemia-reperfusion injury (HIRI) remains a critical complication in liver surgery with limited pharmacological options, and while Farrerol (FA), a natural dihydroflavone, has shown protective effects in other organ IR models, its role in HIRI has never been explored. In this study, we established a murine model of 70% HIRI models and found that intravenous administration of FA (10 and 20 mg/kg) at the onset of reperfusion significantly attenuated HIRI, as evidenced by reduced serum ALT/AST levels, improved histopathology, decreased hepatocyte apoptosis, mitigated oxidative stress, and downregulated inflammatory cytokine expression. To uncover the underlying mechanism, we performed transcriptomic analysis of liver tissues, which unexpectedly identified CD14 as a key target and revealed that FA markedly suppressed the MyD88/NF-κB signaling pathway. Mechanistic validation in LPS-stimulated RAW264.7 macrophages confirmed that FA dose-dependently inhibited M1 polarization and inflammatory responses. Crucially, CD14 overexpression in macrophages largely abrogated the anti‑inflammatory effects of FA. By contrast, CD14 silencing mimicked FA‑mediated suppression of NF‑κB activation and cytokine release, and FA treatment exerted no further inhibitory effects in CD14‑silenced macrophages. Collectively, our findings demonstrate for the first time that FA alleviates HIRI by downregulating macrophage CD14 expression, thereby inhibiting the downstream MyD88/NF-κB pathway and its associated inflammatory cascade, positioning FA as a promising therapeutic candidate and highlighting CD14 as a viable target for HIRI intervention.
GA alleviated LF by modulating PI3K/AKT/NF-κB signaling to inhibit M1 macrophage polarization and the pathogenic macrophage-HSC interaction, highlighting its potential as an immunomodulatory therapeutic candidate for LF.
Jingxin He, Chen Zhang, Yingtian Luo et al.· International Immunopharmaco...· 0 citations
DAP attenuates inflammation and kidney injury in SA-AKI, accompanied by inhibition of non-canonical NF-κB signaling and enhanced autophagic activity and these findings suggest that DAP may represent a promising therapeutic candidate for SAAKI.
Zi-Gang Zhao, Chen Zhang, Xiao-Qiong Zhang et al.· Current Medicinal Chemistry· 0 citations
Mogrol mitigates warm HIRI, at least in part, by activating the PI3K/AKT/GSK3β signaling pathway, thus highlighting its potential as a naturally derived candidate for liver protection.
Wen-Zheng Ruan, Ying Zhu, An Zhao et al.· European Journal of Pharmaco...· 0 citations
Salidroside exerts protective effects in sepsis-associated ALI, which may be associated with modulation of the ERK/FoxO3a signaling axis, improvement of impaired autophagic flux, and maintenance of mitochondrial function.
Specific knockout of the Hrd1 gene in KCs can effectively inhibit the degradation of SOD1-SP1 and the accumulation of ROS, restore autophagic function, thereby promoting the polarization of macrophages toward the M2 phenotype, suppressing the M1 phenotype switch, and exerting hepatoprotective effects.
Ang Li, Jiang-Bo Cao, Yi-Jie Hao et al.· International Journal of Bio...· 0 citations